The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2020Studying the Effects of TMEM175 and CTSB on Glucocerebrosidase Activity and Alpha-synuclein Properties
Promising Outcomes of Original Grant:
The aim of the original grant was to study if there are genes that modify the risk of Parkinson’s disease (PD) or the age at onset of PD, among people who carry... -
Research Grant, 2020Revisiting Alpha-synuclein Pathology Staging and Detection Using an Expanded Antibodies Toolset
Study Rationale:
The levels of alpha-synuclein aggregates and their spreading to different brain region seem to correlate with Parkinson’s disease (PD) progression and symptoms. Increasing evidence... -
Therapeutic Pipeline Program, 2020Novel Candidate against Alpha-synuclein for the Treatment of Parkinson’s Disease
Study Rationale:
The goal of this program is to develop a novel drug for Parkinson’s disease with a unique mechanism of action. We have a drug candidate that shows potential as an inhibitor of alpha... -
Biosample Use Program, 2020Identification of Autoantibodies in People at Risk of Developing Parkinson’s Disease Using Microarrays
Study Rationale:
Autoantibodies are antibodies that mistakenly target and react with a person's own tissues or organs. Autoantibodies can be detected many years before symptoms develop in many... -
Research Grant, 2020GBA Variations, Cholinergic Degeneration, and Cognitive Decline in Parkinson’s Disease
Study Rationale:
Mutations in the GBA gene are the most common genetic risk factors for Parkinson’s disease. People with GBA mutations (GBA-PD) may develop the disease at a younger age and may have... -
Research Grant, 2020Safety and Tolerability of NLX-112 in People with Parkinson’s
Study Rationale:
Motor symptoms of Parkinson’s disease are caused by a lack of brain neurons that carry a neurotransmitter called dopamine, and are commonly treated with levodopa. However, after...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.